Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 12.15 on Friday. The company’s market cap is $562.85 million. The stock’s 50 day moving average price is $11.24 and its 200 day moving average price is $10.69. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.06. The company had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 EPS. On average, analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Major Shareholder Sells $12,000,000.00 in Stock” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/09/16/sucampo-pharmaceuticals-inc-scmp-major-shareholder-sells-12000000-00-in-stock.html.
SCMP has been the topic of a number of recent analyst reports. ValuEngine lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd. TheStreet lowered Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.63.
A number of hedge funds have recently bought and sold shares of SCMP. NEA Management Company LLC bought a new position in Sucampo Pharmaceuticals during the 2nd quarter valued at approximately $13,214,000. Rubric Capital Management LP bought a new stake in shares of Sucampo Pharmaceuticals in the 2nd quarter worth $6,068,000. Vanguard Group Inc. increased its holdings in shares of Sucampo Pharmaceuticals by 48.9% in the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after purchasing an additional 478,226 shares in the last quarter. Royce & Associates LP increased its holdings in shares of Sucampo Pharmaceuticals by 24.6% in the 1st quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock worth $10,714,000 after purchasing an additional 192,000 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Sucampo Pharmaceuticals by 107.3% in the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after purchasing an additional 190,292 shares in the last quarter. 55.44% of the stock is owned by institutional investors.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.